Overview

A+C in Metastatic Lung Adenocarcinoma Cancer

Status:
Unknown status

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

This is a phase II, prospective, single arm, non comparative study with crizotinib combined with bevacizumab in treatment-naive lung adenocarcinoma cancer patients with ALK translocation or ROS1 translocation or MET amplification

Phase:

Phase 2

Details

Lead Sponsor:

Chinese PLA General Hospital

Treatments:

Bevacizumab
Crizotinib